Modification of a series of P2Y12 receptor antagonists by replacement of the ester functionality was aimed at minimizing the risk of in vivo metabolic instability and pharmacokinetic variability. The resulting ketones were then optimized for their P2Y12 antagonistic and anticoagulation effects in combination with their physicochemical and absorption profiles. The most promising compound showed very potent antiplatelet action in vivo. However, pharmacodynamic-pharmacokinetic analysis did not reveal a significant separation between its anti-platelet and bleeding effects. The relevance of receptor binding kinetics to the in vivo profile is described.
Keywords: Acute coronary syndrome (ACS); Acyl sulfonamides; Esters; Ketones; P2Y(12) receptor; Piperidinyl-pyridines; Platelet aggregation; Receptor kinetics; Thromboembolism.
Copyright © 2014 Elsevier Ltd. All rights reserved.